Fasting Versus Nonfasting and Low-Density Lipoprotein Cholesterol Accuracy

被引:90
作者
Sathiyakumar, Vasanth [1 ]
Park, Jihwan [2 ]
Golozar, Asieh [2 ,3 ]
Lazo, Mariana [2 ]
Quispe, Renato [1 ,3 ]
Guallar, Eliseo [2 ,3 ]
Blumenthal, Roger S. [1 ]
Jones, Steven R. [1 ]
Martin, Seth S. [1 ,3 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Ciccarone Ctr Prevent Cardiovasc Dis,Div Cardiol, Baltimore, MD 21205 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[3] Johns Hopkins Bloomberg Sch Publ Hlth, Welch Ctr Prevent Epidemiol & Clin Res, Dept Epidemiol, Baltimore, MD USA
关键词
cholesterol; LDL; data accuracy; fasting; NON-HDL CHOLESTEROL; LDL CHOLESTEROL; CARDIOVASCULAR RISK; LIPID PROFILE; APOLIPOPROTEINS; TRIGLYCERIDES; DISEASE; MANAGEMENT; STATEMENT; EVENTS;
D O I
10.1161/CIRCULATIONAHA.117.030677
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Recent recommendations favoring nonfasting lipid assessment may affect low-density lipoprotein cholesterol (LDL-C) estimation. The novel method of LDL-C estimation (LDL-C-N) uses a flexible approach to derive patient-specific ratios of triglycerides to very low-density lipoprotein cholesterol. This adaptability may confer an accuracy advantage in nonfasting patients over the fixed approach of the classic Friedewald method (LDL-C-F). METHODS: We used a US cross-sectional sample of 1 545 634 patients (959 153 fasting >= 10-12 hours; 586 481 nonfasting) from the second harvest of the Very Large Database of Lipids study to assess for the first time the impact of fasting status on novel LDL-C accuracy. Rapid ultracentrifugation was used to directly measure LDL-C content (LDL-C-D). Accuracy was defined as the percentage of LDL-C D falling within an estimated LDL-C (LDL-C-N or LDL-C-F) category by clinical cut points. For low estimated LDL-C (< 70 mg/dL), we evaluated accuracy by triglyceride levels. The magnitude of absolute and percent differences between LDL-C-D and estimated LDL-C (LDL-C-N or LDL-C-F) was stratified by LDL-C and triglyceride categories. RESULTS: In both fasting and nonfasting samples, accuracy was higher with the novel method across all clinical LDL-C categories (range, 87%-94%) compared with the Friedewald estimation (range, 71%-93%; P= 0.001). With LDL-C < 70 mg/dL, nonfasting LDL-C-N accuracy (92%) was superior to LDL-C-F accuracy (71%; P< 0.001). In this LDL-C range, 19% of fasting and 30% of nonfasting patients had differences >= 10 mg/dL between LDL-C-F and LDL-C-D, whereas only 2% and 3% of patients, respectively, had similar differences with novel estimation. Accuracy of LDL-C < 70 mg/dL further decreased as triglycerides increased, particularly for Friedewald estimation (range, 37%-96%) versus the novel method (range, 82%-94%). With triglycerides of 200 to 399 mg/dL in nonfasting patients, LDL-C N < 70 mg/dL accuracy (82%) was superior to LDL-C-F (37%; P< 0.001). In this triglyceride range, 73% of fasting and 81% of nonfasting patients had >= 10 mg/dL differences between LDL-C-F and LDL-C-D compared with 25% and 20% of patients, respectively, with LDL-C-N. CONCLUSIONS: Novel adaptable LDL-C estimation performs better in nonfasting samples than the fixed Friedewald estimation, with a particular accuracy advantage in settings of low LDL-C and high triglycerides. In addition to stimulating further study, these results may have immediate relevance for guideline committees, laboratory leadership, clinicians, and patients.
引用
收藏
页码:10 / +
页数:21
相关论文
共 39 条
[1]   2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) [J].
Catapano, Alberico L. ;
Graham, Ian ;
De Backer, Guy ;
Wiklund, Olov ;
Chapman, M. John ;
Drexel, Heinz ;
Hoes, Arno W. ;
Jennings, Catriona S. ;
Landmesser, Ulf ;
Pedersen, Terje R. ;
Reiner, Zeljko ;
Riccardi, Gabriele ;
Taskinen, Marja-Riita ;
Tokgozoglu, Lale ;
Verschuren, W. M. Monique ;
Vlachopoulos, Charalambos ;
Wood, David A. ;
Luis Zamorano, Jose .
ATHEROSCLEROSIS, 2016, 253 :281-344
[2]   Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women [J].
Bansal, Sandeep ;
Buring, Julie E. ;
Rifai, Nader ;
Mora, Samia ;
Sacks, Frank M. ;
Ridker, Paul M. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (03) :309-316
[3]   THE INTRAINDIVIDUAL VARIABILITY OF FASTING TRIGLYCERIDE - A CHALLENGE FOR FURTHER STANDARDIZATION [J].
BRENNER, H ;
HEISS, G .
EUROPEAN HEART JOURNAL, 1990, 11 (12) :1054-1058
[4]   Lipid profile, the world needs to change [J].
dos Santos Ferreira, Carlos Eduardo ;
Scartezini, Marileia ;
Franca, Carolina N. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2017, 11 (03) :769-770
[5]   Fasting or Nonfasting Lipid Measurements It Depends on the Question [J].
Driver, Steven L. ;
Martin, Seth S. ;
Gluckman, Ty J. ;
Clary, Julie M. ;
Blumenthal, Roger S. ;
Stone, Neil J. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (10) :1227-1234
[6]   LDL Cholesterol as a Predictor of Mortality, and Beyond To Fast or Not to Fast, That Is the Question? [J].
Eckel, Robert H. .
CIRCULATION, 2014, 130 (07) :528-529
[7]  
FRIEDEWALD WT, 1972, CLIN CHEM, V0018
[8]   Should We Fast Before We Measure Our Lipids? [J].
Gaziano, J. Michael .
ARCHIVES OF INTERNAL MEDICINE, 2012, 172 (22) :1705-1706
[9]   Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [J].
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, R ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Cleeman, JI ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ ;
Keller, SA ;
Jehle, AJ .
CIRCULATION, 2002, 106 (25) :3143-3421
[10]   Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease [J].
Bowman L. ;
Hopewell J.C. ;
Chen F. ;
Wallendszus K. ;
Stevens W. ;
Collins R. ;
Wiviott S.D. ;
Cannon C.P. ;
Braunwald E. ;
Sammons E. ;
Landray M.J. ;
Jiang L. ;
Armitage J. ;
Haynes R. ;
Maggioni A.P. ;
Angermann C.E. ;
Ertl G. ;
Wanner C. ;
Pedersen T. ;
Goto S. ;
Teramoto T. ;
Baigent C. ;
Barter P. ;
Chen Y. ;
Chen Z. ;
Gray A. ;
Mihaylova B. ;
Sleight P. ;
Tobert J. ;
Blaustein R. ;
DeLucca P. ;
Mitchel Y. ;
van Leijenhorst G. ;
Sandercock P. ;
DeMets D. ;
Kjekshus J. ;
Neuberger J. ;
Tonkin A. ;
Emberson J. ;
Granger C. ;
Colhoun H. ;
Barton J. ;
Bray C. ;
Dayanandan R. ;
Knott C. ;
Lay M. ;
Murphy K. ;
Wincott E. ;
Achiri P. ;
Barry S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (13) :1217-1227